Technical Analysis for VRTX - Vertex Pharmaceuticals Incorporated

Grade Last Price % Change Price Change
grade D 176.02 0.13% 0.23
VRTX closed down 0.12 percent on Friday, July 12, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Jul 23

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical VRTX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.13%
Inside Day Range Contraction 0.13%
Fell Below 200 DMA Bearish 0.01%
Fell Below 20 DMA Bearish 0.01%
50 DMA Support Bullish 0.01%
200 DMA Support Bullish -1.53%
20 DMA Support Bullish -1.53%
Bullish Engulfing Bullish -1.37%
Crossed Above 200 DMA Bullish -1.37%
Crossed Above 20 DMA Bullish -1.37%

Older signals for VRTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Its products include telaprevir for the treatment of adults with genotype 1 hepatitis C virus (HCV) infection, which is marketed in the United States and Canada under the INCIVEK brand name; and ivacaftor for the treatment of cystic fibrosis that is marketed in the United States, Canada, and Europe under the KALYDECO brand name. The company, through its collaboration agreement with Janssen Pharmaceutica, N.V., also markets telaprevir in Europe and other countries in Janssen's territories under the INCIVO brand name, as well as in Japan under TELAVIC brand name. It is also developing drug candidates for the treatment of cystic fibrosis, including VX-809, which is in Phase III clinical trial and VX-661 that is in Phase II clinical trial; and drug candidates for the treatment of HCV infection, such as VX-135 (ALS-2200), which is in Phase II clinical trial and VX-222 that is in Phase II clinical trial. In addition, the company develops VX-509, which is in Phase II clinical trial for the treatment of autoimmune disease; and VX-787 that is in Phase II clinical trial for the treatment of influenza. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Chemistry Chemical Compounds Organic Compounds Infection Influenza Cystic Fibrosis Serious Diseases Cyclopropanes Autoimmune Disease Breakthrough Therapy Hepatitis C Virus Organofluorides Treatment Of Cystic Fibrosis HCV Infection
Is VRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 195.81
52 Week Low 151.8
Average Volume 1,041,876
200-Day Moving Average 177.7879
50-Day Moving Average 173.56
20-Day Moving Average 179.0115
10-Day Moving Average 179.212
Average True Range 4.3129
ADX 18.95
+DI 21.2956
-DI 19.3137
Chandelier Exit (Long, 3 ATRs ) 173.3913
Chandelier Exit (Short, 3 ATRs ) 180.7787
Upper Bollinger Band 185.7742
Lower Bollinger Band 172.2488
Percent B (%b) 0.26
BandWidth 7.555604
MACD Line 0.9451
MACD Signal Line 1.6975
MACD Histogram -0.7524
Fundamentals Value
Market Cap 44.33 Billion
Num Shares 252 Million
EPS 1.04
Price-to-Earnings (P/E) Ratio 169.03
Price-to-Sales 17.01
Price-to-Book 21.57
PEG Ratio 1.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 179.27
Resistance 3 (R3) 179.04 177.66 178.69
Resistance 2 (R2) 177.66 176.77 177.77 178.50
Resistance 1 (R1) 176.72 176.22 176.03 176.95 178.30
Pivot Point 175.34 175.34 174.99 175.45 175.34
Support 1 (S1) 174.40 174.45 173.71 174.63 173.28
Support 2 (S2) 173.02 173.90 173.13 173.08
Support 3 (S3) 172.08 173.02 172.89
Support 4 (S4) 172.31